EUCTR2013-002185-39-GB进行中（未招募）1 期
Randomised, Double-Blind, Placebo-Controlled, Phase IIa Study in Healthy Volunteers to Evaluate the Protective Efficacy and Safety of CR8020 in an Influenza Challenge Model
Crucell Holland B.V0 个研究点开始时间: 2013年6月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Male and female subjects = 18 and = 45 years of age
- •2)In good health, with no major medical conditions from medical history, physical examination, and routine laboratory tests as determined by the Investigator at a screening evaluation
- •3)A total body weight =50 kg and a BMI of >18. If the BMI is above 28 the subject may be included if the waist measurement is less than 94 cm (male), or less than 80 cm (female)
- •4)(a)Male subjects must use highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at entry to Quarantine until after the Day 96 (± 5 days) Follow-up Visit.
- •(b)In addition, male subjects must not donate sperm following discharge from Quarantine until after the Day 96 (± 5 days) Follow-up Visit
- •(c)Female subjects must be either:
- •Documented status as surgically sterile or post hysterectomy or-
- •If of childbearing potential, must have a negative serum and urine pregnancy test at SSS and Day -4/-3 and must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at entry to Quarantine and continue until the Day 96 (± 5 days) Follow-up Visit.
- •Acceptable forms of effective contraception include:
- •Established use of oral, injected or implanted hormonal methods of contraception
- •Placement of an intrauterine device (IUD) or intrauterine system (IUS).
- •Barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
- •Male sterilisation (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). [For female subjects on the study, the vasectomised male partner should be the sole partner for that subject].
- •True abstinence: When this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception]
- •5)An informed consent document signed and dated by the subject and Investigator
- •6)Sero-suitable for challenge virus
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Subjects who have a significant history of tobacco use at any time (= total 10 pack year history, e.g. one pack a day for 10 years)
- •2)(a) Females who are pregnant or have been pregnant within six months prior to the study, or who have been breastfeeding within three months prior to screening. Females who have a positive pregnancy test at any point in the study will be withdrawn immediately.
- •(b) Females intending to become pregnant within three months of administration of CR8020 or placebo or males with female partners intending to become pregnant within three months of administration of CR8020 or placebo
- •3) Any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinological, haematological, hepatic, immunological, metabolic, urological, neurological, psychiatric, renal, and/or other major disease or malignancy, as judged by the Investigator
- •4) Abnormal pulmonary function in the opinion of the Investigator as evidenced by clinically significant abnormalities on spirometry
- •5) History or evidence of autoimmune disease or known immunodeficiency of any cause
- •6) Subjects with any history of asthma, COPD, pulmonary hypertension, reactive airway disease, or chronic lung condition of any aetiology (See No. 7 for asthma)
- •7) Asthma (A history of childhood asthma before the age of 12 is acceptable provided the subject is asymptomatic without treatment. Patients with a single episode of wheezing after age 12 (lasting less than eight weeks) can be included at the Investigator's discretion)
- •8) Positive human immunodeficiency virus (HIV), Hepatitis A (HAV), B (HBV), or C (HCV) test
- •9) Any significant abnormality altering the anatomy of the nose or nasopharynx
- •10) Any clinically significant history of epistaxis
- •11) Any nasal or sinus surgery within six months of Viral Challenge
- •12) Recurrent history of clinically significant autonomic dysfunction
- •13) Any abnormal laboratory test or ECG which is deemed by the Investigator(s) to be clinically significant
- •14) Confirmed positive test for drugs of abuse deemed by the Investigator to be clinically significant
- •15) Venous access deemed inadequate for the phlebotomy and cannulation demands of the study
- •16) Known allergy to any of the following:
- •excipients in the Challenge Virus inoculum
- •Any CR8020 excipients (sucrose, L-histidine L-histidine monohydrochloride, polysorbate 20)
- •oseltamivir or other influenza treatments
- •17) Health care workers (e.g. doctors, nurses, medical students and allied healthcare professionals) who work in units with severely immuno-compromised patients (e.g. bone marrow transplant units)
- •18) Presence of household member or close contact(s) (for an additional two weeks after discharge from the isolation facility) who:
- •has known immunodeficiency, is receiving immunosuppressant medication, is undergoing or soon to undergo cancer chemotherapy within 28 days of Viral Challenge, has been diagnosed with emphysema, COPD, or other severe lung disease and resides in a nursing home has received a bone marrow or solid organ transplant
- •19) Evidence of vaccinations within the four weeks prior to Human Viral Challenge
- •Intention to receive travel vaccination(s) before the Day 96 (± 5 days) Follow Up Visit
- •20) Those employed or immediate relatives of those employed at RVL or the Sponsor
- •21) Receipt of blood or blood products, or loss (including blood donations) of 450 mL or more of blood, during the three months prior to Viral Challeng
研究者
相似试验
进行中（未招募）
1 期
Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients With Cardiovascular Disease.Patients With Cardiovascular Disease on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol ReductionMedDRA version: 20.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2020-004392-40-ESIB Therapeutics, LLC900
进行中（未招募）
不适用
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Pemetrexed and Cisplatin plus Enzastaurin versus Pemetrexed and Cisplatin plus Placebo in Chemonaive Patients with Advanced, Unresectable, or Metastatic (Stage IIIB or IV) Nonsquamous Non-Small Cell Lung Cancer - N/Aadvanced, unresectable, or metastatic (stage IIIB or IV) nonsquamous non-small cell lung cancerEUCTR2006-005306-31-BEEli Lilly and Company limited120
已完成
3 期
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With SorafenibHepatocellular CarcinomaJPRN-jRCT2080222919Eli Lilly Japan K.K.
进行中（未招募）
1 期
Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients With Cardiovascular Disease.Patients With Cardiovascular Disease on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol ReductionMedDRA version: 20.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2020-004392-40-DEIB Therapeutics, LLC900
进行中（未招募）
1 期
Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease.Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol ReductionMedDRA version: 20.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2020-004393-22-DEIB Therapeutics, LLC900